Find new ways to fight Covid-19: Black Friday Zamberlan to support research

We are fighting against an enemy we don't know. We will donate 15% of Black Friday's e-commerce revenues to support research.


For Calzaturificio Zamberlan the next Black Friday will be in the name of research. 15% of the e-commerce revenues of the weekend (27-29 November) will be donated to support the foundation Città della Speranza and its fight against Covid-19.
This year has changed our family, social and working habits due to an enemy to whom we have given a name but to whom we are unable to give a face. Fighting against Covid-19 means going down a path without any point of reference, because we still have little information about the behaviour of the immune system in response to the virus. Investing in research is the only way to give us a chance to go back to normal.
"We are living in difficult times," observes Stefano Galvanin, president of Città della Speranza. "Unfortunately, we are extremely weak because we still know very little about this enemy and its behaviour. This is why the Foundation wanted to play an active part, supporting this project in order to open up new ways for treatment".
Città della Speranza: the project
Fondazione Città della Speranza takes the field against Covid-19 by deploying the Pediatric Research Institute for an innovative study that will help to add knowledge to international research, suggest new therapeutic approaches and encourage the development of a vaccine.
The project, for which the Foundation has granted a grant of 500 thousand euros, aims to verify the "immune response to Sars-CoV-2 in the Veneto population" in order to understand what are the effective immune defences against the virus and why they are lacking in some patients.
One of the major problems related to SARS-CoV-2 infection is the lack of information about the type of immunity that the virus generates. It is known that some people are asymptomatic or have mild symptoms (fever, headache, cough), indicating that the immune system has reacted and eliminated the virus.
However, in a range of 10% to 20%, the infection has a complex, sometimes even ominous course. In these cases, patients present a picture of generalized inflammation because the immune system was unable to activate a correct response immediately, allowing the virus to replicate while remaining localized at the lung level. Hence the need to deepen the analysis of the pulmonary infiltrate and the cytokinic microenvironment.
Unlike in the adult population, in children, on the other hand, the infection has a rather light course, with symptoms such as fever, inflammation of the upper respiratory tract (rhinitis, otitis, pharyngitis) and more rarely of the lower respiratory tract (bronchitis, bronchiolitis, pneumonia). What causes the increased resistance of children is unclear, but understanding the mechanisms could provide an important key to the development of targeted therapies. The most robust hypotheses at the scientific level refer to a "younger" immune system than that of adults and the presence of partial immunity due to exposure to other viruses or vaccines.
By analysing the blood samples of asymptomatic, fear-symptomatic and symptomatic patients, both pediatric and adult, through the most innovative analysis techniques, the scientific project will make it possible to evaluate specific parameters in order to achieve the following characterization of the immune response to SARS-CoV-2.